HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Manufacturing Practices Survey Proposed By FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA is proposing to conduct a survey of dietary supplement companies' existing manufacturing practices for use in developing its proposed rule on industry-wide GMP standards, the agency says in an Oct. 6 Federal Register notice.

You may also be interested in...

Only 16% Of Supplement Makers Surveyed Report AEs To FDA - GMP Study

A scant 37 (16% of 238) dietary supplement establishments that responded to an FDA manufacturing practices survey said they report consumer complaints of adverse events to FDA.

Supplement GMPs Should Proceed Despite Economic Concerns - CRN, Rexall

Concerns over the economic burden that small companies will face when implementing Good Manufacturing Practices for dietary supplements should not delay or unduly affect FDA's rulemaking, industry commenters advise.

Industry dietary supplement GMP proposal published for comments in ANPR.

DIETARY SUPPLEMENT GMPs: "COMPETENT MEDICAL" EVALUATION OF REPORTED ADVERSE EVENTS may be needed to "determine whether follow-up action is necessary to protect the public health," FDA states in an advanced notice of proposed rulemaking on current Good Manufacturing Practice regs for dietary supplements. The notice, published in the Feb. 6 Federal Register, requests comments on an industry proposal for dietary supplement GMPs and a number of related GMP topics, including the appropriate review of adverse event reports. Comments will be accepted by the agency through May 7.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts